Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 10, 2008. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than general financial performance.
Material Changes
A re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan ("The Plan") resulted in an increase in the notional allocation of Ordinary Share ADRs on March 7, 2008. The transaction occurred at a price of $42.41 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items beyond the specific transaction notification. The event was disclosed in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: March 7, 2008 (Notification date: March 10, 2008).
- Transaction Price: $42.41 per ADR.
- Involved Parties: Dr M Slaoui (59 shares), Dr R G Greig (238 shares), Mr W C Louv (82 shares), Dr D Pulman (75 shares), and Mr C Viehbacher (57 shares).
- Context: The increase in allocation was due to a re-valuation of the cash element within the US Retirement Savings Plan.